MCID: INT079
MIFTS: 52

Intrahepatic Cholangiocarcinoma

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Intrahepatic Cholangiocarcinoma

MalaCards integrated aliases for Intrahepatic Cholangiocarcinoma:

Name: Intrahepatic Cholangiocarcinoma 12 53 15 73
Cholangiocarcinoma 44 73
Peripheral Intrahepatic Cholangiocarcinoma 73
Intrahepatic Bile Duct Carcinoma 12
Peripheral Cholangiocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4928
ICD10 33 C22.1
MeSH 44 D018281
NCIt 50 C35417
SNOMED-CT 68 109842005

Summaries for Intrahepatic Cholangiocarcinoma

NIH Rare Diseases : 53 Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation.

MalaCards based summary : Intrahepatic Cholangiocarcinoma, also known as cholangiocarcinoma, is related to mucinous intrahepatic cholangiocarcinoma and lymphoepithelioma-like carcinoma, and has symptoms including abdominal pain and malaise. An important gene associated with Intrahepatic Cholangiocarcinoma is TUG1 (Taurine Up-Regulated 1
We found that TUG1 is upregulated in ICC samples, which correlates with poor prognosis and adverse clinical pathological characteristics. Knockdown of TUG1 inhibited the proliferation, motility, and invasiveness of cultured ICC cells, and decreased tumor burden in a xenograft mouse model. When we explored the mechanisms underlying these effects, we found that TUG1 acts as an endogenous competing RNA (ceRNA) that 'sponges' miR-145, thereby preventing the degradation of Sirt3 mRNA and increasing expression of Sirt3 and GDH proteins. Accordingly, glutamine consumption, ?-KG production, and ATP levels were dramatically decreased by TUG1 knockdown in ICC cells, and this effect was reversed by miR-145 inhibition.
Dysfunction Pattern: Regulation [up-regulated]), and among its related pathways/superpathways are Gastric cancer and CLEC7A (Dectin-1) signaling. The drugs Gemcitabine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and colon, and related phenotype is neoplasm.

Related Diseases for Intrahepatic Cholangiocarcinoma

Diseases related to Intrahepatic Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)
# Related Disease Score Top Affiliating Genes
1 mucinous intrahepatic cholangiocarcinoma 35.0 IDH1 MUC2
2 lymphoepithelioma-like carcinoma 31.2 CDH1 KRT7 MUC1
3 cystadenocarcinoma 30.8 KRT7 MUC1 MUC2 TP53
4 adenocarcinoma 30.7 CDH1 FGFR2 KRAS MUC1 MUC4 TP53
5 biliary papillomatosis 30.6 KRAS KRT7 MUC1 MUC2 TP53
6 cholangiocarcinoma 30.3 AFP CCAT2 CDH1 FGFR2 IDH1 IDH2
7 pancreas adenocarcinoma 30.3 CDH1 KRAS MUC1 MUC2 MUC4 TP53
8 renal cell carcinoma, nonpapillary 30.0 CCAT1 CDH1 KRT7 MUC1 TUG1
9 gallbladder cancer 30.0 CCAT1 CDH1 KRAS MUC2 TP53 TUG1
10 squamous cell carcinoma 29.1 CCAT2 CDH1 FGFR2 KRAS MUC1 TP53
11 lung squamous cell carcinoma 28.9 CCAT1 CCAT2 CDH1 FGFR2 KRAS TP53
12 colorectal cancer 26.8 CCAT1 CCAT2 CDH1 IDH1 IDH2 KRAS
13 hepatocellular carcinoma 25.8 AFP CCAT1 CCAT2 CDH1 CPS1-IT1 IDH1
14 pancreatic cancer 25.4 CCAT1 CDH1 KRAS MIR127 MIR214 MIR376A1
15 sarcomatous intrahepatic cholangiocarcinoma 12.3
16 signet ring cell intrahepatic cholangiocarcinoma 12.2
17 rare adenocarcinoma of the breast 11.1 KRAS TP53
18 solid adenocarcinoma with mucin production 11.1 KRT7 MUC1
19 apocrine adenoma 11.1 KRAS MUC1
20 cap polyposis 11.1 MUC2 MUC4
21 cerebellar astrocytoma 11.1 IDH1 TP53
22 interval angle-closure glaucoma 11.1 IDH1 IDH2
23 pancreatic intraductal papillary-mucinous neoplasm 11.0 MUC1 MUC2
24 adult oligodendroglioma 11.0 IDH1 IDH2
25 enchondroma 11.0 IDH1 IDH2
26 malignant spiradenoma 11.0 KRT7 TP53
27 intrahepatic bile duct adenoma 11.0 AFP KRT7
28 protoplasmic astrocytoma 11.0 IDH2 TP53
29 tumor of exocrine pancreas 11.0 MUC1 MUC2
30 sinonasal undifferentiated carcinoma 11.0 IDH2 MUC1
31 adenomyoma 11.0 KRT7 MUC1 MUC4
32 cerebral convexity meningioma 11.0 CDH1 TP53
33 hyperplastic polyposis syndrome 11.0 KRAS TP53
34 chronic ethmoiditis 11.0 MUC1 MUC2 MUC4
35 endosalpingiosis 11.0 KRT7 MUC1
36 spiradenoma 11.0 KRT7 MUC1 TP53
37 ethmoid sinusitis 11.0 MUC1 MUC2 MUC4
38 breast secretory carcinoma 11.0 KRT7 MUC1 MUC4
39 vulvar intraepithelial neoplasia 11.0 CDH1 TP53
40 parachordoma 11.0 KRT7 MUC1
41 nasal cavity adenocarcinoma 11.0 KRAS KRT7 TP53
42 female reproductive endometrioid cancer 11.0 KRT7 TP53
43 middle ear adenoma 11.0 KRT7 MUC1
44 colorectal cancer 1 10.9 MUC1 MUC2 MUC4
45 mixed cell type cancer 10.9 KRAS KRT7 TP53
46 intracranial chondrosarcoma 10.9 IDH1 IDH2 TP53
47 colloid carcinoma of the pancreas 10.9 KRAS MUC1 MUC2
48 ovary adenocarcinoma 10.9 KRAS KRT7 TP53
49 mature teratoma 10.9 AFP KRAS TP53
50 glioma susceptibility 1 10.9 IDH1 IDH2 TP53

Graphical network of the top 20 diseases related to Intrahepatic Cholangiocarcinoma:



Diseases related to Intrahepatic Cholangiocarcinoma

Symptoms & Phenotypes for Intrahepatic Cholangiocarcinoma

UMLS symptoms related to Intrahepatic Cholangiocarcinoma:


abdominal pain, malaise

MGI Mouse Phenotypes related to Intrahepatic Cholangiocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 IDH2 KRAS MUC2 TP53 AFP CDH1

Drugs & Therapeutics for Intrahepatic Cholangiocarcinoma

Drugs for Intrahepatic Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 95058-81-4 60750
2
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
3
Capecitabine Approved, Investigational Phase 3,Phase 1 154361-50-9 60953
4
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
5
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
6
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
7
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
8 Alkylating Agents Phase 2, Phase 3
9 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
10 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
11 Antimetabolites Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
12 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
13 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
14 Antiviral Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
15 Mitogens Phase 3,Phase 1,Phase 2
16 Endothelial Growth Factors Phase 3
17 Pharmaceutical Solutions Phase 3
18 Antineoplastic Agents, Alkylating Phase 2, Phase 3
19
Metformin Approved Phase 1, Phase 2 657-24-9 14219 4091
20
chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
21
Fluorouracil Approved Phase 2 51-21-8 3385
22
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
23
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
24
Floxuridine Approved Phase 2,Phase 1 50-91-9 5790
25
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
26
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
27
Pertuzumab Approved Phase 2 145040-37-5, 380610-27-5 2540
28
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
29
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
30
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
31
Adenosine Approved, Investigational Phase 2 58-61-7 60961
32
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
33
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
34
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
35
Trametinib Approved Phase 2 871700-17-3 11707110
36
nivolumab Approved Phase 2 946414-94-4
37
Ramucirumab Approved, Investigational Phase 2 947687-13-0
38
Osimertinib Approved Phase 2 1421373-65-0 71496458
39
Racepinephrine Approved Phase 2 329-65-7 838
40
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
41
Calcitriol Approved, Nutraceutical Phase 2 32222-06-3 134070 5280453
42
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
43
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
44
Doxil Approved June 1999 Phase 2 31703
45 Chloroquine diphosphate Phase 1, Phase 2 50-63-5
46 Analgesics Phase 1, Phase 2
47 Micronutrients Phase 2
48 Mitomycins Phase 2
49 Analgesics, Non-Narcotic Phase 1, Phase 2
50 Hormone Antagonists Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
2 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
3 A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03251443 Phase 3 Apatinib
4 Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma Recruiting NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
5 Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery Recruiting NCT02200042 Phase 3 Cisplatin;Gemcitabine Hydrochloride
6 Bortezomib in Intrahepatic Cholangiocellular Carcinoma Recruiting NCT03345303 Phase 3 Bortezomib
7 A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma Withdrawn NCT03081039 Phase 3 Carboplatin;Cisplatin;Gemcitabine
8 Calcitriol in Advanced Intrahepatic Cholangiocarcinoma Unknown status NCT01039181 Phase 2 Calcitriol
9 Metformin And Chloroquine in IDH1/2-mutated Solid Tumors Unknown status NCT02496741 Phase 1, Phase 2 Metformin and chloroquine combination
10 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Completed NCT02428855 Phase 2 Dasatinib
11 Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma Completed NCT01912053 Phase 2
12 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
13 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma Completed NCT01954745 Phase 2 Cabozantinib
14 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymp Completed NCT02273739 Phase 1, Phase 2 AG-221
15 A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy Completed NCT00587067 Phase 2 FLOXURIDINE
16 A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma Recruiting NCT02994251 Phase 2 gemcitabine;Cisplatin;Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
17 Liver Transplantation for Early Intrahepatic Cholangiocarcinoma Recruiting NCT02878473 Phase 2
18 ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03230318 Phase 2 ARQ 087
19 Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin Recruiting NCT01648023 Phase 2 Gem-Cis or Gem-Carbo
20 Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) Recruiting NCT01862315 Phase 2 Floxuridine (FUDR);dexamethasone;Gemcitabine;Oxaliplatin
21 A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03521219 Phase 2 Apatinib
22 Treatment for Bile Duct Cancer in the Liver Recruiting NCT02167711 Phase 2 SIRT Yttrium-90
23 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
24 Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Recruiting NCT03201458 Phase 2 Atezolizumab;Cobimetinib
25 SHR-1210 in Combination With GEMOX in Patients With Advanced BTC Recruiting NCT03486678 Phase 2 SHR-1210+GEMOX
26 Ramucirumab for Advanced Pre-Treated Biliary Cancers Recruiting NCT02520141 Phase 2 Ramucirumab
27 Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer Recruiting NCT03044587 Phase 2 Arm NaI-IRI + 5-FU + Leucovorin (Arm A);Arm Cisplatin + Gemcitabine (Arm B)
28 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting NCT02465060 Phase 2 Adavosertib;Afatinib;Binimetinib;Capivasertib;Crizotinib;Dabrafenib;Dasatinib;Defactinib;FGFR Inhibitor AZD4547;Larotrectinib;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Vismodegib
29 Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations Active, not recruiting NCT01752920 Phase 1, Phase 2 ARQ 087
30 Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers Active, not recruiting NCT02392637 Phase 2 Abraxane (Nab-Paclitaxel);Cisplatin;Gemcitabine
31 Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma Not yet recruiting NCT03364530 Phase 2 Gemcitabine-Oxaliplatin Regimen
32 Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer Not yet recruiting NCT03579771 Phase 2 Cisplatin;Gemcitabine;Nab-paclitaxel
33 Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma Suspended NCT02415036 Phase 2 Melphalan
34 Study of Low-Dose Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Intrahepatic Cholangiocarcinoma Terminated NCT02254681 Phase 2 Gemcitabine;Cisplatin
35 Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION Terminated NCT01383746 Phase 1, Phase 2
36 Response of Hepatic Tumors to Radioembolization Withdrawn NCT01775280 Phase 2
37 Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma Completed NCT01668134 Phase 1
38 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery Completed NCT01825603 Phase 1 ADH-1;Cisplatin;Gemcitabine Hydrochloride
39 Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma Recruiting NCT02834780 Phase 1 H3B-6527
40 Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma Recruiting NCT01525069 Phase 1 Floxuridine;Dexamethasone;Gemcitabine;Oxaliplatin
41 Phase I Study of BAY 1436032 in Patients With IDH1-mutant Solid Tumors Recruiting NCT02746081 Phase 1 BAY1436032
42 Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting NCT03257761 Phase 1 Guadecitabine
43 Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangioc Recruiting NCT03267940 Phase 1 PEGylated Recombinant Human Hyaluronidase;Cisplatin;Gemcitabine;Atezolizumab
44 Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma Active, not recruiting NCT01938729 Phase 1 FLOXURIDINE;DEXAMETHASONE;GEMCITABINE
45 Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases Active, not recruiting NCT00858429 Phase 1 capecitabine
46 Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery Withdrawn NCT03117855 Phase 1 Capecitabine
47 Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma Withdrawn NCT02856568 Phase 1 Cisplatin;Gemcitabine Hydrochloride;Ricolinostat
48 Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma Unknown status NCT02526771 Not Applicable
49 Next Generation Sequencing in Intrahepatic Cholangiocarcinoma Unknown status NCT02184871
50 Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients Unknown status NCT01914289 Not Applicable

Search NIH Clinical Center for Intrahepatic Cholangiocarcinoma

Cochrane evidence based reviews: cholangiocarcinoma

Genetic Tests for Intrahepatic Cholangiocarcinoma

Anatomical Context for Intrahepatic Cholangiocarcinoma

MalaCards organs/tissues related to Intrahepatic Cholangiocarcinoma:

41
Liver, Lymph Node, Colon, Endothelial, T Cells, Testes, Bone

Publications for Intrahepatic Cholangiocarcinoma

Articles related to Intrahepatic Cholangiocarcinoma:

(show top 50) (show all 841)
# Title Authors Year
1
Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of I^-Catenin. ( 29415992 )
2018
2
Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system. ( 29434290 )
2018
3
MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7. ( 29387225 )
2018
4
Characterization and prognostic significance of mortalin, Bcl-2 and Bax in intrahepatic cholangiocarcinoma. ( 29434920 )
2018
5
Challenges of surgical management of intrahepatic cholangiocarcinoma. ( 29911912 )
2018
6
Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis. ( 29947010 )
2018
7
Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression. ( 29869103 )
2018
8
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. ( 29874985 )
2018
9
Role of palliative radiotherapy in unresectable intrahepatic cholangiocarcinoma: population-based analysis with propensity score matching. ( 29942151 )
2018
10
Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. ( 29887261 )
2018
11
Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells. ( 29805605 )
2018
12
Small intestinal obstruction due to the metastasis of intrahepatic cholangiocarcinoma: A case report. ( 29561438 )
2018
13
Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. ( 29935812 )
2018
14
Prognostic comparison of the 7th and 8th editions of the American Joint Commission on Cancer staging system for intrahepatic cholangiocarcinoma. ( 29450978 )
2018
15
RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis. ( 29913454 )
2018
16
Upregulation of long nona89coding RNA CCAT2 indicates a poor prognosis and promotes proliferation and metastasis in intrahepatic cholangiocarcinoma. ( 29393466 )
2018
17
The expression and clinicopathological role of CDX2 in intrahepatic cholangiocarcinoma. ( 29862152 )
2018
18
Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. ( 29963132 )
2018
19
B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma. ( 29696716 )
2018
20
Comparison of the sixth and the seventh editions of the UICC classification for intrahepatic cholangiocarcinoma. ( 29859128 )
2018
21
Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System. ( 28424987 )
2018
22
Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. ( 29805522 )
2018
23
Towards Personalized Medicine for Intrahepatic Cholangiocarcinoma: Pharmacogenomic Stratification of Patients. ( 29394502 )
2018
24
Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes. ( 29299649 )
2018
25
Impact of serum CA19-9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma. ( 29427472 )
2018
26
Intrahepatic cholangiocarcinoma after Fontan procedure in an adult with visceral heterotaxy. ( 29559246 )
2018
27
Y90 radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: Glass versus resin microspheres. ( 29448165 )
2018
28
Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling. ( 29446253 )
2018
29
Optimal extent of surgical and pathologic lymph node evaluation for resected intrahepatic cholangiocarcinoma. ( 29370972 )
2018
30
Overexpression of IL-35 in intrahepatic cholangiocarcinoma isa prognostic indicator after curative resection. ( 29446854 )
2018
31
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. ( 29871612 )
2018
32
Is there a role for Ytrrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma? ( 29395023 )
2018
33
Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. ( 29398035 )
2018
34
Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. ( 29408647 )
2018
35
Long-term outcomes of patients with intraductal growth sub-type of intrahepatic cholangiocarcinoma. ( 29958811 )
2018
36
Tourniquet-ALPPS is a promising treatment for very large hepatocellular carcinoma and intrahepatic cholangiocarcinoma. ( 29963276 )
2018
37
Correction to: Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-NaA^ve Patients. ( 29380003 )
2018
38
The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. ( 29903509 )
2018
39
Extended left hepatectomy for intrahepatic cholangiocarcinoma: hepatic vein reconstruction with in-situ hypothermic perfusion and extracorporeal membrane oxygenation. ( 29386002 )
2018
40
Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? A propensity score-matched analysis. ( 29450868 )
2018
41
Visceral infiltration of intrahepatic cholangiocarcinoma is most prognostic after curative resection - Retrospective cohort study of 102 consecutive liver resections from a single center. ( 29803768 )
2018
42
Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014. ( 29893702 )
2018
43
Intrahepatic cholangiocarcinoma patients without indications of lymph node metastasis not benefit from lymph node dissection. ( 29371948 )
2017
44
Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014. ( 28765978 )
2017
45
LncRNA-CCAT1 Promotes Migration, Invasion, and EMT in Intrahepatic Cholangiocarcinoma Through Suppressing miR-152. ( 28921383 )
2017
46
ALPPS in a patient with periductal infiltrating intrahepatic cholangiocarcinoma. ( 29264586 )
2017
47
The risk factors and prognostic factors of intrahepatic cholangiocarcinoma. ( 28089545 )
2017
48
Intrahepatic cholangiocarcinoma. ( 28094162 )
2017
49
CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma. ( 28576144 )
2017
50
Intrahepatic cholangiocarcinoma arising from HBV infection may be a highly selected population for liver transplantation. ( 28759704 )
2017

Variations for Intrahepatic Cholangiocarcinoma

Expression for Intrahepatic Cholangiocarcinoma

Search GEO for disease gene expression data for Intrahepatic Cholangiocarcinoma.

Pathways for Intrahepatic Cholangiocarcinoma

GO Terms for Intrahepatic Cholangiocarcinoma

Cellular components related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC4

Biological processes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 O-glycan processing GO:0016266 9.43 MUC1 MUC2 MUC4
2 positive regulation of cellular senescence GO:2000774 9.4 KRAS MIR22
3 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.37 MUC1 TP53
4 maintenance of gastrointestinal epithelium GO:0030277 9.32 MUC2 MUC4
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.26 KRAS MUC1 MUC2 MUC4
6 isocitrate metabolic process GO:0006102 9.16 IDH1 IDH2
7 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 isocitrate dehydrogenase activity GO:0004448 8.96 IDH1 IDH2
2 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.62 IDH1 IDH2

Sources for Intrahepatic Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....